Sign up for information on the next Ideal Experience click here

P2P IDEAL®: Telephonic Teaching Rounds Updates
Sign up for the next Teaching Rounds Updates Click Here


Program References:

Panel 1 
ACC/AHA 2006 Atrial Fibrillation Guidelines Circulation. 2006;114:e257-e354.

Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131(9):688-695.

Panel 2
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
JAMA. 2001;285(22):2864-2870.

ACC/AHA 2006 Atrial Fibrillation Guidelines Circulation. 2006;114:e257-e354.

Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial ibrillation. Chest. 2010;137(2):263-272.

Pisters R, Lane DA, Nieuwlaat R, et al. Chest. 2010, doi:10.1378/chest.10-0134

Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.

Jackson K, Gersh BJ, Stockbridge N, et al. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. Am Heart J. 2008;155(5):829-840.

Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153(6):1006-12.

Panel 3
Lafuente-Lafuente C, Mahé I, Extramiana F. Management of atrial fibrillation.
BMJ. 2009 Dec 23;339:b5216. doi: 10.1136/bmj.b5216.

ACC/AHA/ESC 2006 guidelines for the Management of Patients with Atrial Fibrillation. Circulation. 2006;114:e257-e354.

Lee TH. Atrial fibrillation guidelines. In: Libby P, Bonow RO, Zipes DP, eds.
Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th   ed. Philadelphia, PA: Saunders; 2008:923-931.
Panel 4 
ACC/AHA/ESC 2006 guidelines for the Management of Patients with Atrial Fibrillation. Circulation. 2006; 114:e257-e354.

Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115(18):3827-3834.

Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30(4):330-338.

Panel 5
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.

Pradaxa® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2010.

ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340-347.

Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331-339.

Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159(3):348-353.e1.

Connolly SJ, Yusuf S, et al ESC 2010 Aug 31

Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48). Am Heart J.

yed TM, Halperin JL. Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges. Nat Clin Pract Cardiovasc Med. 2007;4(8):428-435.

Panel 6
ACC/AHA 2006 Atrial Fibrillation Guidelines Circulation. 2006;114:e257-e354.